Hanxuan Li, Zhousheng Xiao, L. Darryl Quarles* and Wei Li* Pages 1489 - 1507 ( 19 )
Osteoporosis is a pathological loss of bone mass due to an imbalance in bone remodeling where osteoclast-mediated bone resorption exceeds osteoblast-mediated bone formation resulting in skeletal fragility and fractures. Anti-resorptive agents, such as bisphosphonates and SERMs, and anabolic drugs that stimulate bone formation, including PTH analogues and sclerostin inhibitors, are current treatments for osteoporosis. Despite their efficacy, severe side effects and loss of potency may limit the long term usage of a single drug. Sequential and combinational use of current drugs, such as switching from an anabolic to an anti-resorptive agent, may provide an alternative approach. Moreover, there are novel drugs being developed against emerging new targets such as Cathepsin K and 17β-HSD2 that may have less side effects. This review will summarize the molecular mechanisms of osteoporosis, current drugs for osteoporosis treatment, and new drug development strategies.
Osteoporosis, bone remodeling, osteoclasts, osteoblasts, osteocytes, antiresorptive drugs, anabolic drugs.
Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, 38165, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, 38165, Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163